€0.13 MDG1.DE Medigene AG (XETRA) on 23 Mar 2026: Oversold bounce trade plan

MDG1.DE stock trades at €0.1335 intraday on XETRA after a heavy sell-off, setting up a classic oversold bounce scenario. The share price fell 27.64% today with volume near 189,470 shares, well above the 50,000 average. For intraday traders in Germany, this price, the high intraday volatility and a clear support zone near the year low offer an actionable short-term setup. We outline the fundamentals, technical triggers, Meyka AI grade and a practical trade plan for risk-aware bounce attempts.

MDG1.DE stock intraday price action and liquidity

Today MDG1.DE stock opened at €0.16 and touched a day low of €0.08 and a day high of €0.16 on XETRA. The move shows a one-day drop of 27.64% from the previous close of €0.18.

Volume surged to 189,470 versus an average volume of 43,152, giving intraday traders clear liquidity to enter and exit positions. Immediate support sits near the year low €0.11 and resistance appears near €0.16–€0.18 on short-term charts.

MDG1.DE stock fundamentals and balance sheet context

Medigene AG reports EPS of -1.21 and a negative PE ratio near -0.11, reflecting ongoing R&D losses. Market capitalization is tiny at €1,967,470, and shares outstanding are 14,737,600.

Key balance metrics show cash per share €1.36 and book value per share €1.72, while operating cash flow per share is -1.23. The company’s liquidity ratios support continued operations, but persistent negative margins and free cash flow stress the risk profile for investors.

MDG1.DE stock technical setup for an oversold bounce

Price averages are far above current levels: 50-day at €1.41 and 200-day at €1.66, confirming a long-term downtrend but creating mean-reversion potential for a bounce. The stock’s 3‑month return is -91.91%, signalling extreme oversold pressure.

Intraday signals to watch: a volume spike with a price hold above €0.11, a firm close above €0.16, and a failure to retest the day low €0.08. Use tight stops and scale size given the stock’s high relative volatility (relVolume 4.39).

MDG1.DE stock Meyka grade and analyst perspective

Meyka AI rates MDG1.DE with a score out of 100: 61.75, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Independent company ratings show weakness across profitability metrics, but Meyka’s grade reflects balance between asset value (cash and book value) and headline risks. These grades are informational and not advice.

MDG1.DE stock valuation, catalysts and risks

Valuation metrics are mixed: price-to-sales 0.33 and price-to-book 0.08 suggest the market prices in severe downside. Catalysts include clinical updates on T cell therapies and collaborations like 2seventy bio. Upcoming public earnings date listed is 2025-07-31 and should be monitored for guidance.

Primary risks are thin market cap (€1.97M), continued cash burn, volatile trading, and negative operating margins. Positive trial results would be a strong upside catalyst given the low valuation.

MDG1.DE stock trade plan and Meyka AI forecast

For intraday oversold bounce traders, a plan: enter partial size on a confirmed reversal above €0.16–€0.18, set a stop below €0.11, and target an initial exit near €0.30. Risk per trade should be capped and position sized to withstand sharp swings.

Meyka AI’s forecast model projects a short-term bounce target of €0.30, which implies an upside of 124.69% versus the current price €0.1335. Longer recovery scenarios center near €0.80 over 12 months, an implied upside of 499.44%. Forecasts are model-based projections and not guarantees. Sources: Medigene website and Medigene LinkedIn.

Final Thoughts

MDG1.DE stock at €0.1335 presents a high-risk, high-volatility oversold bounce opportunity on XETRA in Germany. Intraday traders can look for a volume-backed reversal above €0.16 and manage risk with a stop beneath the year low €0.11. Fundamentals remain weak, with EPS -1.21, negative cash flow per share, and a micro market cap of roughly €1.97M, so any bounce is tactical not structural. Meyka AI rates MDG1.DE 61.75/100 (B, HOLD) and models a short-term bounce to €0.30 (+124.69%) and a recovery scenario to €0.80 (+499.44%) over 12 months. Use tight risk controls, watch clinical and earnings updates, and remember forecasts are projections not guarantees. Meyka AI provides this as an AI-powered market analysis platform insight to inform your trading plan.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.